Teva has been sitting on the sidelines for more than a year as its peers jumped head-first into a biopharma deal bonanza. But no longer: The Israeli company struck a $3.2 billion agreement to buy Auspex Pharmaceuticals, which will finally put it back onto the M&A map. And it's zeroing in on more deal targets, analysts say.
The European Commission is concerned that the $13.4 billion acquisition of Biomet by Zimmer will result in price increases due to reduced competition in orthopedic implants in the European Economic Area. In order to allay these fears, Zimmer has agreed to divest three businesses in specific European markets.
Ireland-based Horizon Pharma snatched up Hyperion Therapeutics for $1.1 billion to get its hands on the company's rare disease meds, diversifying its portfolio and expanding its footprint in the orphan drug market.
The M&A rumor mill was churning Friday morning on reports of an in-the-works Shire ($SHPG) deal for orphan drugmaker BioMarin Pharmaceuticals.
Shire is an acquisitive company with a focus on rare diseases. BioMarin fits the same description. A blog post that, by its own admission, "might be codswallop," reported that the former is considering buying the latter. And those three facts combined to send the shares of BioMarin, far from a penny stock, up as much as 15% on Friday, illustrating how the biotech boom has changed Wall Street's perception of the drug industry.
Hearing devices have not been among Medtronic's competencies--until now. The medical device giant has bought magnetic hearing implant startup Sophono for an undisclosed amount. Sophono's implant is the smallest and most effective at higher frequencies, according to the startup and Medtronic.
Gastro drug developer Synergy Pharmaceuticals is considering putting itself up for sale, Bloomberg reports, perhaps emboldened by the high price secured by competitor Salix Pharmaceuticals.
Adding $10 billion to its stock buyback program might mean Merck & Co. wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
It's try, try again for Egypt-based Amoun Pharmaceuticals. The drugmaker, among the largest in its home country, hired Goldman Sachs to look for potential buyers after previous efforts failed.
Now that Actavis' $66 billion Allergan buy--and the bitter takeover war between Allergan and Valeant that preceded it--are in the books, there's much to reflect on. And a lot of lingering questions about how the saga will impact dealmaking moving forward, too.